Ampio Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing novel therapies for prevalent inflammatory conditions.

According to the law firm press release, the lawsuit alleges Defendants made false and/or misleading statements and/or failed to disclose that: (1) the clinical research organization conducting the STEP Study lacked independence; (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than permitted by the drug specifications; and (3) as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Plaintiffs filed a consolidated Complaint on February 8, 2016.

On August 4, 2016, the Court issued an Order granting without prejudice Defendants' Motion to Dismiss. Plaintiffs were given leave to file an amended Complaint, which they did on September 27.

On January 31, 2017, the parties entered into a Stipulation of Settlement. The Settlement was preliminarily approved by the Court on April 5. On September 29, the Court granted final approval of the Settlement and dismissed this case with prejudice. On April 16, 2018, the Court issued an Order granting Plaintiffs' Motion for distribution of Settlement funds.